EDIT vs JAZZ · rev $32.3M vs P/E 1988, rev $4.07B
Editas Medicine Inc (EDIT) versus Jazz Pharmaceuticals PLC (JAZZ) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
EDIT currently screens at market cap $375.2M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Not investment advice. Open the EDIT and JAZZ stock pages for the full models.
Not investment advice.